To Rebuild Zicam, Matrixx Can Tap Into Brand's History, Pharmacists' Regard
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives' best chances for rebuilding the Zicam brand appear to be reminding consumers why they initially chose the firm's products and tapping pharmacists' insight on the efficacy of zinc-containing cold remedies
You may also be interested in...
Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time
Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time
Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time